Azitra has a broad pipeline of medical dermatology products


Our Pipeline

Azitra’s product pipeline includes four live biotherapeutic product candidates in development, including one in clinical stage studies.

Azitra has changed all product name designations from "AZT" to "ATR".

Bioactive compounds derived from skin commensals

A deep dive into how commensal bacteria work may identify bioactive compounds that could provide additional solutions to skin diseases with limited treatment options. It could also ultimately lead to a new class of antimicrobials, which would be particularly valuable in the midst of growing antibiotic resistance.

Azitra maintains a robust research program investigating the bioactive compounds within the skin microbiome. The potential of microbe-based medicine has attracted significant investment from private investors and the government, including a grant from the U.S. Department of Defense to explore the ability of Staphylococcus epidermidis (SE) to inhibit Staphylococcus aureus (SA), which has become resistant to traditional antibiotics. In collaboration with scientists at the Jackson Laboratory in Farmington, CT, we are also characterizing the native antibiotics produced by SE and engineering strains of SE to produce therapeutic levels of those bioactive compounds that can be applied to the skin. If successful, this platform could be extended beyond SE and SA as a broader tool for novel antibiotic discovery


Our skin microbiome plays a crucial role in maintaining human health

Azitra is leveraging the microbiome to solve the challenges of skin disease and adverse skin conditions through three strategies:

Learn more